Get the Stockscreener App
4.75
5.32%
0.24
Vanda Pharmaceuticals Inc stock is traded at $4.75, with a volume of 340.38K.
It is up +5.32% in the last 24 hours and up +0.85% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$4.51
Open:
$4.52
24h Volume:
340.38K
Relative Volume:
0.73
Market Cap:
$280.67M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
90.65
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
+8.94%
1M Performance:
+0.85%
6M Performance:
+7.22%
1Y Performance:
-10.38%
1-Day Range:
$4.52
$4.7801
1-Week Range:
$4.42
$4.875
52-Week Range:
$3.8092
$5.545
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.75 | 269.45M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Published on: 2025-08-21 02:56:29 - newsyoung.net
Vanda says court ruling opens door for Hetlioz jet lag indication - MSN
Technical analysis overview for Vanda Pharmaceuticals Inc. stockWeekly Stock Recap & Real-Time Market Sentiment Alerts - Newser
Is Vanda Pharmaceuticals Inc. reversing from oversold territory2025 Big Picture & Real-Time Volume Surge Alerts - Newser
What indicators show strength in Vanda Pharmaceuticals Inc.Quarterly Risk Review & Free Expert Verified Stock Movement Alerts - Newser
Understanding Vanda Pharmaceuticals Inc.’s price movementJuly 2025 EndofMonth & Precise Entry and Exit Recommendations - Newser
Multi asset correlation models including Vanda Pharmaceuticals Inc.2025 Institutional Moves & Community Consensus Picks - Newser
Vanda Pharmaceuticals' Regulatory Breakthrough: A New Dawn for Hetlioz and Investor Confidence - AInvest
Vanda Pharmaceuticals gets big win in court against FDA for sleep disorder drug - The Business Journals
Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark - Stocktwits
Vanda Pharma granted favourable Court ruling over FDA’s Hetlioz approvability - TipRanks
In a major win for Vanda, a federal appeals court overturns FDA's order denying approval of Hetlioz for the treatment of jet lag disorder - MarketScreener
Vanda Pharmaceuticals Secures Victory Over FDA in Jet Lag Disorder Treatment Dispute - AInvest
Vanda Pharmaceuticals shares rise after court overturns FDA denial By Investing.com - Investing.com Canada
Regulatory Reckoning: How Vanda's Legal Victory Reshapes Biopharma's Risk-Reward Landscape - AInvest
Vanda Pharmaceuticals wins court battle against FDA over jet lag drug - Investing.com
Vanda Pharmaceuticals shares rise 5.05% premarket after winning a landmark victory over the FDA. - AInvest
Federal Court Overturns FDA: Vanda's Jet Lag Drug Hetlioz Shows 'Significant Improvement' in Trials - Stock Titan
Can Vanda Pharmaceuticals Inc. benefit from deglobalizationTrade Ideas & Real-Time Stock Movement Alerts - sundaytimes.kr
Comparing Vanda Pharmaceuticals Inc. in custom built stock radars2025 Key Lessons & Safe Entry Trade Signal Reports - Newser
Technical signs of recovery in Vanda Pharmaceuticals Inc.2025 Market Overview & Daily Risk Controlled Trade Plans - Newser
Can swing trading help recover from Vanda Pharmaceuticals Inc. losses2025 Big Picture & Capital Efficiency Focused Ideas - Newser
Reversal indicators forming on Vanda Pharmaceuticals Inc. stockDay Trade & Expert Approved Trade Ideas - Newser
Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionJuly 2025 Drop Watch & Expert Curated Trade Setup Alerts - Newser
Can volume confirm reversal in Vanda Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Reliable Momentum Entry Alerts - Newser
What makes Vanda Pharmaceuticals Inc. stock price move sharplyJuly 2025 Setups & Daily Profit Maximizing Tips - thegnnews.com
Sentiment analysis tools applied to Vanda Pharmaceuticals Inc.July 2025 Breakouts & Free Reliable Trade Execution Plans - Newser
Leading vs lagging indicators on Vanda Pharmaceuticals Inc. performancePortfolio Value Summary & Consistent Profit Trading Strategies - Newser
Will a bounce in Vanda Pharmaceuticals Inc. offer an exitJuly 2025 Opening Moves & Technical Buy Zone Confirmations - Newser
What moving averages say about Vanda Pharmaceuticals Inc.Dividend Hike & Daily Chart Pattern Signal Reports - Newser
Is Vanda Pharmaceuticals Inc. stock poised for growthJuly 2025 Decliners & Accurate Technical Buy Alerts - Newser
Vanda’s Jet Lag Drug Gets Fresh FDA Look After Court Ruling (1) - Bloomberg Law News
Vanda Pharmaceuticals Receives Strong Buy Rating Amidst Growth in Key Product Lines and Promising FDA Decision on Bysanti - AInvest
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus
Vanda Pharmaceuticals CEO Buys 10,000 Shares at $4.15/Share on August 7, 2023. - AInvest
Vanda (VNDA) Q2 Revenue Rises 4% - AOL.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Cut to Strong Sell at Wall Street Zen - Defense World
Vanda Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - Jammu Links News
What is the dividend policy of Vanda Pharmaceuticals Inc. stockSuperior returns - Jammu Links News
Is Vanda Pharmaceuticals Inc. stock overvalued or undervaluedCapitalize on emerging growth stocks - Jammu Links News
What are Vanda Pharmaceuticals Inc. company’s key revenue driversRapidly growing investment returns - Jammu Links News
What institutional investors are buying Vanda Pharmaceuticals Inc. stockRapid growth trajectories - Jammu Links News
What catalysts could drive Vanda Pharmaceuticals Inc. stock higher in 2025Unlock your portfolio’s full growth potential - Jammu Links News
Why is Vanda Pharmaceuticals Inc. stock attracting strong analyst attentionMaximize portfolio value with timely trades - Jammu Links News
What are the technical indicators suggesting about Vanda Pharmaceuticals Inc.Maximize your portfolio’s earning power - Jammu Links News
Is Vanda Pharmaceuticals Inc. a growth stock or a value stockDiscover stocks with massive upside potential - Jammu Links News
Should I hold or sell Vanda Pharmaceuticals Inc. stock in 2025Phenomenal wealth increase - Jammu Links News
How many analysts rate Vanda Pharmaceuticals Inc. as a “Buy”Get professional advice for market timing - Jammu Links News
Vanda Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vanda Pharmaceuticals Inc Stock (VNDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mitchell Stephen Ray | Director |
Jun 13 '25 |
Sale |
4.59 |
7,000 |
32,130 |
97,082 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):